Loading...

Valneva SE

VLA.PAEURONEXT
Healthcare
Biotechnology
3.32
0.08(2.47%)

Valneva SE (VLA.PA) Stock Competitors & Peer Comparison

See (VLA.PA) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
VLA.PA€3.32+2.47%550.3M-5.78-€0.56N/A
UCB.BR€185.05+3.87%34B32.58€5.49+0.67%
ARGX.BR€517.20+2.62%31.3B36.66€13.96N/A
TUB.BR€146.00+2.53%6.3B70.30€2.02+0.63%
ABVX.PA€59.20+3.86%3.6B-19.32-€2.95N/A
GLPG.AS€27.94+2.72%1.9B-6.50-€4.38N/A
GTBP.PA€280.50+0.00%626.7M-4.10-€68.39N/A
PHARM.AS€0.85-1.05%596.1M-43.50-€0.02N/A
MEDCL.PA€17.12+0.06%570.6M-15.83-€1.09N/A
IVA.PA€2.93+6.16%382.5M-0.89-€3.08N/A
Showing 1 to 10 of 69 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

VLA.PA vs UCB.BR Comparison July 2025

VLA.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VLA.PA stands at 550.3M. In comparison, UCB.BR has a market cap of 34B. Regarding current trading prices, VLA.PA is priced at €3.32, while UCB.BR trades at €185.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VLA.PA currently has a P/E ratio of -5.78, whereas UCB.BR's P/E ratio is 32.58. In terms of profitability, VLA.PA's ROE is -0.43%, compared to UCB.BR's ROE of +0.11%. Regarding short-term risk, VLA.PA is more volatile compared to UCB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for VLA.PA.Check UCB.BR's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;